a_dose_of_drug_smallbanner_R2

Blog News - A Dose of Drug Development is a web publication produced by Integrium. The blog post content included conveys subjects of discussion and practice in the drug development process along with real-time Integrium activity. Readers interested in following are welcome to comment and interact on the Integrium website blog space.


Integrium, LLC Executives to Attend RESI on MaRS 2017!

By: Emily MacHale

Tustin, CA – Integrium, LLC Executives will attend RESI on MaRS 2017 in Toronto, Canada on April 4, 2017. Hosted each year, RESI is notorious for providing meetings for hungry fundraisers and allowing them to connect with eager life science investors. Guests will also be able to hear from investors and their firsthand experience with the investing process and the best tactics for qualifying candidates.

RESI gives Integrium Executives the chance to market their products and services to fundraisers in the life sciences field in hopes to find ways to collaborate on various levels. Through powerful synergy discussions and room for networking, Integrium Executives are always able to create new relationships with biotechs, medical device companies, investors, and more.

Integrium Executives will be available for meetings at various times throughout RESI. Details are upon meeting request. To reserve a timeslot to meet with Integrium, click below or contact Emily MacHale at emily.machale@integrium.com.

About Integrium

Integrium helps Micro Cap, Small Cap, and Privately held Biotechs within the Generic and Innovator space attain clinical data so they can raise the next round of capital. lntegrium's areas of therapeutic focus include Cardiovascular, Metabolic, Renal, Inflammatory, Dermatology, Wound Healing, Gene Therapy, and Orphan Diseases. Secondary specialties include Schedule 2 drugs and Oncology

To learn more about Integrium, contact:

Emily MacHale
Associate Director of Marketing & Research
emily.machale@integrium.com
908-375-2009

Click here to reserve a meeting


Integrium, LLC Executives to Attend 2017 MassBio Annual Meeting!

By: Emily MacHale

Tustin, CA – Integrium, LLC Executives are attending the 2017 MassBio Annual Meeting in Boston, MA on March 30 – 31, 2017. Each year, the Integrium team is happy to be a part of the fast-paced program the Massachusetts Life Sciences industry offers.

“We are always excited to watch the Massachusetts biotechnology ecosystem engage in keynote presentations, discussions, workshops, networking meetings, and more,” states Michael Loftus, Executive Director of Business Development.

With the number of topics the meeting provides, Integrium especially looks forward to discussions around biotechs funding and emerging markets. As Integrium helps biotechnology, medical device, and diagnostic companies attain clinical data to raise their next round of capital, learning more about the funding industry is a major benefit to Integrium Executives. It is always a pleasure learning from industry experts, keynote speakers, and special guests on their view of our everchanging biotech ecosystem.

Integrium Executives will be available for meetings throughout MassBio at varying times and locations. Details are upon meeting request. To reserve a timeslot to meet with Integrium, click to register below or contact Emily MacHale at Emily.MacHale@integrium.com.

About Integrium

Integrium helps Micro Cap, Small Cap, and Privately held Biotechs within the Generic and Innovator space attain clinical data so they can raise the next round of capital. lntegrium's areas of therapeutic focus include Cardiovascular, Metabolic, Renal, Inflammatory, Dermatology, Wound Healing, Gene Therapy, and Orphan Diseases. Secondary specialties include Schedule 2 drugs and Oncology

To learn more about Integrium, contact:

Emily MacHale
Associate Director of Marketing & Research
Emily.MacHaIe@Integrium.com
908-375-2009

Click to Register


Integrium, LLC Executives to Attend DCAT Week 2017!

By: Emily MacHale

Tustin, CA – Members of the Integrium Executive Management Team will be attending DCAT Week 2017 in New York City on March 20th through 23rd. DCAT Week 2017 is different from previous years because of the improvements and changes to many of the meeting spaces, networking events, venues, and more. Integrium Executives look forward to DCAT Week each year and are especially excited to see the additions to the program this year.

Throughout a full week of networking events, business seminars, and dinner receptions, Integrium Executives use this time to learn more about the current pharmaceutical market and ways to advance business development and investment techniques. Specifically, Integrium looks forward to enhancing their knowledge in the generics pharmaceutical market within leading therapeutic areas. Partnership seminars are also of extreme value to Integrium as they are constantly looking to develop new relationships with biotechs, investors, consultants, and beyond to expand and meet business needs.

Integrium will be available for meetings throughout DCAT Week 2017 at varying times and locations. Details are upon meeting request. To reserve a timeslot to meet with Integrium, click to register below or contact Emily MacHale at Emily.MacHale@integrium.com.

About Integrium

Integrium helps Micro Cap, Small Cap, and Privately held Biotechs within the Generic and Innovator space attain clinical data so they can raise the next round of capital. lntegrium's areas of therapeutic focus include Cardiovascular, Metabolic, Renal, Inflammatory, Dermatology, Wound Healing, Gene Therapy, and Orphan Diseases. Secondary specialties include Schedule 2 drugs and Oncology

To learn more about Integrium, contact:

Emily MacHale
Associate Director of Marketing & Research
Emily.MacHaIe@Integrium.com
908-375-2009

Click to Register


Integrium, LLC Launches Newly Revamped Company Website

Tustin, CA – Integrium, LLC, a full-service Clinical Proof of Concept (PoC) Firm, announced today the launch of its newly revamped company website. This updated website offers quick and easy navigation throughout the company’s portals of clinical trial therapeutic experience and key CRO services with detailed information. With easy access to assistance for prospective clients interested in partnerships, availability for tips, guidance or advice from our founders and key leadership, the new website allows users to gain all answers to their questions with just a few clicks.

The new website has a sleek look with enriched content developed from recent years of success, met goals, new clientele and relationships, gained therapeutic expertise, and beyond. Integrium, LLC hopes the launch of the new website will provide viewers with enough information to stay updated on our services, experience, and recent events and lead them to contacting us for collaboration or potential relationships.

"We are excited regarding the new look and feel of the Integrium website. We pride ourselves on giving our clients full access to our capital raising partners, clinical development expertise, and all other contacts within our biotech ecosystem," mentioned Mike Loftus, Executive Director of Business Development.

Integrium’s new site will continuously be updated with current events about clinical trials and projects we are involved in, future events we will attend, blogs related to our expertise, and new product information. Integrium encourages website visitors to contact us using our messaging portal or direct phone number for feedback on the website or any requested information about our products and services. On behalf of everyone at Integrium, LLC, we hope you enjoy our new website!

About Integrium

Through a trusted partnership with Proof of Concept (PoC) Capital, Integrium is able to assist Micro Cap, Small Cap, and Privately held Biotechs looking to raise additional financing, by providing new clinical data to create the next bump in valuation. Integrium’s areas of therapeutic focus include Cardiovascular, Metabolic, Renal, Inflammatory, Dermatology, Wound Healing, Gene Therapy, and Orphan Diseases.

Contact

To learn more about Integrium Clinical Research, please contact:

Mike Loftus
Executive Director, Business Development
Phone: (908) 295-4578
Email: Mike.Loftus@integrium.com

Emily MacHale
Associate Director, Marketing & Research
Phone: 908-375-2009
Email: Emily.MacHale@integrium.com

Click to Register


Integrium, LLC Executives to Attend 2017 American Academy of Dermatology Annual Meeting.

By: Emily MacHale

Tustin, CA - Integrium, LLC Executives will be attending the American Academy of Dermatology (AAD) Annual Meeting on Friday, March 3rd, 2017 in Orlando, FL. Bringing together dermatology companies across the map each year, Integrium finds AAD Annual Meeting to be an important time to connect with key opinion leaders to discover new trends and news in the dermatology arena.

Taking part in each session led by industry experts provides guests with the knowledge to offer their customers, patients, and beyond with the information needed to be successful within the dermatology sector. The program offers a wide variety of engaging sessions and meetings that are extremely useful to Integrium in their journey to expanding their dermatological therapeutic experience.

Integrium, LLC will be available for meetings on Friday, March 3rd, 2017 at the Orange County Convention Center - West Building. To reserve a time slot to meet with Integrium, register below!

About Integrium

Integrium helps Micro Cap, Small Cap, and Privately held Biotechs within the Generic and Innovator space attain clinical data so they can raise the next round of capital. lntegrium's areas of therapeutic focus include Cardiovascular, Metabolic, Renal, Inflammatory, Dermatology, Wound Healing, Gene Therapy, and Orphan Diseases. Secondary specialties include Schedule 2 drugs and Oncology

To learn more about Integrium, contact:

Emily MacHale
Associate Director of Marketing & Research
Emily.MacHaIe@Integrium.com
908-375-2009

Click to Register


Integrium, LLC to Attend: Why Invest in Philadelphia Now? Converting Risk Capital to Success Stories

lifeTustin, CA - Integrium, LLC and Life Sciences Collaborative Executives will be in attendance at Why Invest in Philadelphia Now? Converting Risk Capital to Success Stories on March 7, 2017.

Agenda

Life Sciences Collaborative will host a panel of discussions during their March 2017 event. Topics will include: how to hold an effective meeting, translating good science into a return on investment, investment troubles within the life sciences community, challenges related to different levels of investments, and more.

Panelists include C-Level folks from a wide variety of biotechs and life science companies. They will touch on ways life science entrepreneurs can become more active in the Philadelphia metro area with raising capital, obtaining seed money, acquiring funding, and beyond.

Interested in attending? Register!